Artículo

Drug-based cancer therapy to overcome immune resistance by steering tumor evolution

Fernandez, ArielIcon
Fecha de publicación: 01/2019
Editorial: Informa Healthcare
Revista: Expert Opinion On Drug Discovery
ISSN: 1746-0441
Idioma: Inglés
Tipo de recurso: Artículo publicado
Clasificación temática:

Resumen

We argue that therapy must lead rather than follow vis-à-vis cancer evolution. Clinical experience suggests that the evading phenotype resulting from treatment can never be fully anticipated or eliminated when a single source of selection pressure is applied during treatment. Thus, therapy must steer cancer evolution and LIC may well become the underlying paradigm to overcome resistance in a therapeutic context where immune surveillance is maintained.
Palabras clave: CANCER EVOLUTION , CANCER RESISTANCE , IMMUNE CHECKPOINT INHIBITOR , IMMUNE EVASION , PHOSPHOINOSITIDE-3 KINASE INHIBITOR , TARGETED THERAPY
 
Archivos asociados
Thumbnail
 
Tamaño: 940.2Kb
Formato: PDF
.
Licencia
info:eu-repo/semantics/openAccess Excepto donde se diga explícitamente, este item se publica bajo la siguiente descripción: Creative Commons Attribution-NonCommercial-ShareAlike 2.5 Unported (CC BY-NC-SA 2.5)
Identificadores
URI: http://hdl.handle.net/11336/151968
URL: https://www.tandfonline.com/doi/full/10.1080/17460441.2019.1550066
DOI: http://dx.doi.org/10.1080/17460441.2019.1550066
Colecciones
Articulos(INQUISUR)
Articulos de INST.DE QUIMICA DEL SUR
Citación
Fernandez, Ariel; Drug-based cancer therapy to overcome immune resistance by steering tumor evolution; Informa Healthcare; Expert Opinion On Drug Discovery; 14; 1; 1-2019; 5-8
Compartir
Altmétricas